Real-World Data of Light Chain (AL) Amyloidosis: Prognostic Indices and Treatment Patterns

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Limited real-world data exists on AL amyloidosis diagnostic and treatment patterns.
• Analysis of real-world data is crucial for understanding patient characteristics and outcomes.

Purpose of the Study:

• To analyze the characteristics, treatment approaches, and clinical outcomes of AL amyloidosis patients in real-world settings.
• To evaluate the impact of different treatment regimens on patient survival and response rates.

Main Methods:

• Retrospective analysis of real-world data from 60 AL amyloidosis patients.
• Evaluation of treatment regimens including Bortezomib (Bz)-based and alkylating-based regimens.
• Assessment of cardiac involvement using Mayo Clinical Stage (CS) and Revised-Mayo CS.

Main Results:

• Bortezomib-based regimens followed by high-dose therapy with Melphalan and autologous stem cell transplantation (HDT + ASCT) showed superior hematologic, cardiac, and renal response rates.
• Patients receiving CyBorD induction followed by HDT + ASCT demonstrated significantly durable overall survival (OS).
• Advanced cardiac involvement and response rates were identified as significant prognostic factors.

Conclusions:

• Bortezomib-based combinations significantly improve survival in AL amyloidosis patients.
• Advanced cardiac involvement and response rates remain adverse prognostic indicators.
• Real-world data provides valuable insights into AL amyloidosis management and outcomes.